08-23-07

Dkt. No. 29248/29

ED STATES PATENT AND TRADEMARK OFFICE

Applicants

Erik Buntinx

Appl. No.

10/580,962

Filed

May 31, 2006

For

USE OF D4 AND 5-HT2A ANTAGONISTS, INVERSE

AGONISTS OR PARTIAL AGONISTS

Group Art

1617

Examiner

RAMACHANDRAN, UMAMAHESWARI

Customer No.

1912

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

"Express Mail" mailing label No. EV 725836717 US Date of Deposit: August 22, 2007

I hereby certify that this paper or fee is being deposited with the United States Postal Service Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria,

Name:

VA 22313-14

Signature:

Sir:

This Supplemental Information Disclosure Statement (SIDS) is being filed to supplement the Information Disclosure Statement filed on April 12, 2007 and May 31, 2006 in connection with the subject application.

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicant would like to direct the Examiner's attention to the references that are listed on the attached form PTO/SB/08A-B. A copy of each non-U.S. patent documents is also

Applicant: Erik Buntinx Serial No.: 10/580,962

Filed: May 31, 2006

Page 2

attached. These references were cited in an Office Action issued on August 10, 2007 in connection with U.S. Patent Application No. 10/984,683 and an Office Action issued on May 3, 2007 in connection with U.S. Patent Application No. 10/803,793.

Applicant is submitting the subject Supplemental Information Disclosure Statement pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Accordingly, no fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required in connection with this submission or to maintain the pendency of the subject application, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP

Attorneys for Applicant

90 Park Avenue

New York, New York 10016

(212) 336-8000

Dated: August 22, 2007

New York, New York

Alan D.Miller, Reg. No. 42,889

PTO/SB/08A (04-07)

Approved for use through 09/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

ute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known		
Application Number	10/580,962	
Filing Date	May 31, 2006	
First Named Inventor	Erik Buntinx	
Art Unit	1617	
Examiner Name	Umamaheswari Ramachandran	
Attorney Docket Number	29248/29	

				T DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	^{US-} 5,446,070	08-29-1995	Mantelle	
	2	^{US-} 6,300,354	10-09-2001	Steiner et al.	
	3	US- 2004/0002482	01-01-2004	Dudley et al.	
		US-			
	r .	ı	ı		

	FORE	IGN PATENT DOCU	MENTS		
Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Τ
	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	٢
 					┡
					┢
					┢

Examiner	Date	
Signature	Considered	
	1	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND** TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Palent and Trademark Deduction Act of 1995, no persons are required to respect to sollection of informatic pulsors it contains a valid OMB control purpose.

	e for form 1449/PTO	vork Reduction Act of 1995, no persons are required to respond to a collection of info			Complete if Known
Cabbinan	3101101111 1443/1 10			Application Number	10/580,962
INFO	PRMATION	DIS	CLOSURE	Filing Date	May 31, 2006
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Erik Buntinx
(Use as many sheets as necessary)			ecessanvi	Art Unit	1617
	(300 10 1111) 611011 10 11001111)		Examiner Name	Umamaheswari Ramachandran	
Sheet	2	of	2	Attorney Docket Number	29248/29

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No. ¹	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	4	HUBBLE J P et al., entitled "Pre-clinical studies of pramipexole: clinical relevance," European Journal of Neurology Supplement, 2000, Vol. 7 (Suppl. 1), pp. 15-20.	
	5	SILVER D E et al., entitled "Initiating therapy for Parkinson's disease," Neurology, 1998, Vol. 50 (Suppl. 6), pp. S18-S22.	
			- 15.5 1.1.131
			•

Signature Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.